COVID-19 drug remdesivir recommended for EU approvalThe EMA’s human medicines committee (CHMP) has recommended granting a conditional marketing authorisation to Gilead’s COVID-19 treatment remdesivir Share XCOVID-19 drug remdesivir recommended for EU approvalhttps://pharmaphorum.com/news/covid-19-drug-remdesivir-recommended-for-eu-approval/
Gilead files remdesivir for EU approval, with a verdict possible “in weeks”The EMA has said it will fast-track the review of Gilead Sciences’ remdesivir as a treatment for COVID-19, Share XGilead files remdesivir for EU approval, with a verdict possible “in weeks”https://pharmaphorum.com/news/gilead-files-remdesivir-for-eu-approval-with-a-verdict-possible-in-weeks/
EU regulators warn over safety of Trump’s favourite COVID drugsAs the search for therapies for COVID-19 continues, European regulators have urged caution over the cardiac side-effects of Share XEU regulators warn over safety of Trump’s favourite COVID drugshttps://pharmaphorum.com/news/eu-regulators-warn-over-safety-of-trumps-favourite-covid-drug/
EMA won’t clear chloroquine for COVID-19 without trial dataThe European drugs regulator has stopped short of granting widespread use of the drug chloroquine against COVID-19, days Share XEMA won’t clear chloroquine for COVID-19 without trial datahttps://pharmaphorum.com/news/ema-refuses-to-clear-chloroquine-for-covid-19-without-data/
CHMP backs safety of anticoagulants after real-world studyThe EMA’s human drugs advisory committee has said that no change is needed to the use of direct Share XCHMP backs safety of anticoagulants after real-world studyhttps://pharmaphorum.com/news/chmp-backs-safety-of-anticoagulants-after-real-world-study/
Novartis closes on EU approval for SMA gene therapy ZolgensmaNovartis is on the final straight to approval of its spinal muscular atrophy (SMA) gene therapy Zolgensma in Share XNovartis closes on EU approval for SMA gene therapy Zolgensmahttps://pharmaphorum.com/news/novartis-closes-on-eu-approval-for-sma-gene-therapy-zolgensma/
Pfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’Pfizer’s Vyndaqel has become the first drug to be approved for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in Europe, Share XPfizer’s EU Vyndaqel okay ‘sets up $1.5bn sales next year’https://pharmaphorum.com/news/pfizers-eu-vyndaqel-okay-sets-up-1-5bn-sales-next-year/
Dutch biotech sector feel benefits of EMA move, says industry leaderThe Netherlands’ biotech sector has already seen an upswing following the relocation of the European Medicines Agency (EMA) Share XDutch biotech sector feel benefits of EMA move, says industry leaderhttps://pharmaphorum.com/news/dutch-biotech-feeling-benefits-of-ema-relocation-says-industry-leader/
EMA proposes 10 recommendations to unlock potential of big dataEuropean regulators have proposed ten recommendations that aim to unlock the potential of big data for public health Share XEMA proposes 10 recommendations to unlock potential of big datahttps://pharmaphorum.com/news/ema-proposes-10-recommendations-to-unlock-potential-of-big-data/
